| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385665A1 Modulation of enos activity and therapeutic uses thereof |
| 05/10/2001 | CA2382455A1 Nucleic acids and proteins from group b streptococcus |
| 05/09/2001 | EP1098199A1 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease |
| 05/09/2001 | EP1097988A1 Process for culturing cells in a monolayer |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097721A2 Oil-based adjuvant vaccine |
| 05/09/2001 | EP1097715A1 Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097210A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 05/09/2001 | EP1097208A2 Compositions and methods for therapy and diagnosis of prostate cancer |
| 05/09/2001 | EP1097203A1 Human presenilin-associated protein |
| 05/09/2001 | EP1097202A2 Human transport protein homologs |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097174A1 Lupus anticoagulant antibody to f1 region of prothrombin |
| 05/09/2001 | EP1097172A1 Anti hepatitis c virus antibody and uses thereof |
| 05/09/2001 | EP1097168A2 Compounds and methods for modulating cadherin-mediated functions |
| 05/09/2001 | EP1096955A2 Cancer treatment methods using antibodies to aminophospholipids |
| 05/09/2001 | EP1096954A2 Adjuvant and vaccine compositions containing monophosphoryl lipid a |
| 05/09/2001 | EP1096953A1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 05/09/2001 | EP1096952A2 Polysaccharide vaccine for staphylococcal infections |
| 05/09/2001 | EP1096949A2 Treatment of celiac disease with interleukin-15 antagonists |
| 05/09/2001 | EP1096946A2 Delta cleavage products and methods based thereon |
| 05/09/2001 | EP0514411B1 Polypeptides and dna encoding same, associated with human malaria parasites |
| 05/09/2001 | CN1294632A Compsns. derived from i(mycobacterium vaccae) and methods for their use |
| 05/09/2001 | CN1294628A Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B |
| 05/09/2001 | CN1294625A Novel polymerizable fatty acids, phospholipids and poly merized liposomes therefrom |
| 05/09/2001 | CN1294517A Immunoglobulin molecules having synthetic variable region and modified specificity |
| 05/08/2001 | US6229005 DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent |
| 05/08/2001 | US6228991 Amino acid sequence; diagnosis, treatment or prevention of reproductive, developmental, neoplastic, and immunological/ autoimmune disorders; anticarcinogenic agents; antitumor/antiarthrtic/antidiabetic agents; endometriosis |
| 05/08/2001 | US6228987 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| 05/08/2001 | US6228983 Peptides from transmembrane protein, gp41, from human immunodeficiency virus; viricides; drug screening; intracellular modulators of coiled-coil peptide structures |
| 05/08/2001 | US6228846 Polynucleotide vaccine formula against canine pathologies |
| 05/08/2001 | US6228838 Bactericide or antibiotic screening; genetic engineering |
| 05/08/2001 | US6228837 Endothelial monocyte activating polypeptide II: a mediator which activates host response |
| 05/08/2001 | US6228835 Decorin binding protein compositions |
| 05/08/2001 | US6228649 Double targeted gene replacement in unicellular diploid organisms |
| 05/08/2001 | US6228640 Producing cells which activate immune response to specific disease by incubating cd34 hematopoietic stem cells with serum and cell growth factors, incubating with material from diseased cells, and adding tumor necrosis factor-alpha |
| 05/08/2001 | US6228627 Mur A-1 from Streptococcus pneumoniae |
| 05/08/2001 | US6228621 Plasmids encoding immunogenic proteins and intracellular targeting sequences |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228612 Compounds |
| 05/08/2001 | US6228608 Recombinant FIV glycoprotein 160 and P24 gag protein |
| 05/08/2001 | US6228594 Method for determining the presence or absence of a hereditary hemochromatosis gene mutation |
| 05/08/2001 | US6228584 Nucleotide sequences for use in the detection of streptococcus |
| 05/08/2001 | US6228576 Detecting enzymes inhibitor of a preferential polymerase; incubate sample and inhibitor, detect polymerase activity |
| 05/08/2001 | US6228423 Biodegradable targetable microparticle delivery system |
| 05/08/2001 | US6228372 Polypeptides with amino acid sequences and peptides |
| 05/08/2001 | US6228371 Peptide sequences |
| 05/08/2001 | US6228368 Antigens for human papilloma virus capsomere and fusion proteins adjacent to amino acid residues |
| 05/08/2001 | US6228364 Isolation of polypeptides with sequences |
| 05/08/2001 | US6228362 Boron neutron capture therapy using pre-targeting methods |
| 05/08/2001 | US6228361 Antisticking agents to prevent bonding |
| 05/08/2001 | US6228360 Immunoglobulins binding to human von willebrand factor with chains |
| 05/08/2001 | US6228357 Cancer therapy using an oncogene product and a foreign MHC molecule |
| 05/08/2001 | CA2096010C Recombinant feline coronavirus s proteins |
| 05/08/2001 | CA2087003C Hrsv vaccine |
| 05/08/2001 | CA2066661C Viral vaccine conjugates |
| 05/08/2001 | CA2011896C Ringworm vaccine |
| 05/03/2001 | WO2001031343A2 Diagnosis and therapy of cancer using sgp28-related molecules |
| 05/03/2001 | WO2001031046A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 05/03/2001 | WO2001031045A1 Mammalian-type glycosylation in plants |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031019A2 Neisserial antigenic peptides |
| 05/03/2001 | WO2001031015A2 36p6d5: secreted tumor antigen |
| 05/03/2001 | WO2001031011A2 Gene mining system and method |
| 05/03/2001 | WO2001031009A2 Chandra: a th1-specific gene |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001031003A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 05/03/2001 | WO2001030989A2 Method for creating divergent populations of nucleic acid molecules and proteins |
| 05/03/2001 | WO2001030972A2 Regulation of gene expression by neuroleptic agents |
| 05/03/2001 | WO2001030969A2 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | WO2001030854A2 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin |
| 05/03/2001 | WO2001030848A2 Nucleic acids of the human abc1 gene and applications thereof |
| 05/03/2001 | WO2001030847A1 Modified gp100 and uses thereof |
| 05/03/2001 | WO2001030828A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | WO2001030817A1 Immunogenic proteins from the domestic mite, blomia tropicalis |
| 05/03/2001 | WO2001030816A1 NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Ph1 p 6 ALLERGEN AND THEIR USE |
| 05/03/2001 | WO2001030815A1 Redox reversible hcv proteins with native-like conformation |
| 05/03/2001 | WO2001030814A1 Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv |
| 05/03/2001 | WO2001030812A2 Activation of hcv-specific t cells |
| 05/03/2001 | WO2001030809A1 Cyclic peptides and aids vaccines |
| 05/03/2001 | WO2001030806A1 Polynucleotides and polypeptides involved in biofilm biology and their uses |
| 05/03/2001 | WO2001030393A2 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 05/03/2001 | WO2001030392A2 Delivery of proteins across polar epithelial cell layers |
| 05/03/2001 | WO2001030390A2 Method |
| 05/03/2001 | WO2001030386A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | WO2001030385A1 Adjuvants for nucleic acid vaccines |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030382A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/03/2001 | WO2001030381A2 Use of csf-1 inhibitors |
| 05/03/2001 | WO2001030378A1 A method of prophylaxis and treatment |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2001016164A3 Treatment of allergic rhinitis |
| 05/03/2001 | WO2001005968A9 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |